Get the Stockscreener App
37.49
3.00%
-1.18
Exelixis Inc stock is traded at $37.49, with a volume of 2.75M.
It is down -3.00% in the last 24 hours and down -6.44% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$38.67
Open:
$37.55
24h Volume:
2.75M
Relative Volume:
1.03
Market Cap:
$10.09B
Revenue:
$2.17B
Net Income/Loss:
$521.27M
P/E Ratio:
21.18
EPS:
1.77
Net Cash Flow:
$633.79M
1W Performance:
-6.20%
1M Performance:
-6.44%
6M Performance:
-5.28%
1Y Performance:
+9.93%
1-Day Range:
$36.00
$38.41
1-Week Range:
$36.00
$40.62
52-Week Range:
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
37.49 | 10.41B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-19-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Initiated | Goldman | Buy |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
EXEL Downgraded to Neutral by Guggenheim on November 3, 2025 | E - GuruFocus
Can Exelixis Inc. stock weather global recessionWeekly Trend Recap & High Accuracy Swing Trade Signals - newser.com
Real time alert setup for Exelixis Inc. performanceM&A Rumor & Weekly High Conviction Ideas - newser.com
Will Exelixis Inc. (EX9) stock rise with strong economyQuarterly Profit Report & Real-Time Volume Analysis Alerts - newser.com
Guggenheim Downgrades Exelixis to Neutral From Buy - MarketScreener
How Exelixis Inc. (EX9) stock reacts to Fed tightening2025 Buyback Activity & Expert Approved Trade Ideas - newser.com
How to escape a deep drawdown in Exelixis Inc.July 2025 Summary & Free Daily Entry Point Trade Alerts - newser.com
Exelixis Inc. stock trend forecast2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - newser.com
How Exelixis Inc. stock trades before earningsIPO Watch & Weekly Watchlist for Hot Stocks - newser.com
Can you recover from losses in Exelixis Inc.Market Growth Summary & Daily Chart Pattern Signals - newser.com
Understanding Exelixis Inc.’s price movement2025 Market Sentiment & Weekly Stock Breakout Alerts - newser.com
Using data filters to optimize entry into Exelixis Inc.July 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
Exelixis Q2 2025 slides: cabozantinib franchise grows 19% YoY, NET launch gains traction - Investing.com Nigeria
Why Exelixis Inc. stock could benefit from AI revolutionEarnings Beat & AI Optimized Trade Strategies - newser.com
Will Exelixis Inc. (EX9) stock beat Nasdaq index returns2025 Analyst Calls & Growth Focused Entry Reports - newser.com
How Exelixis Inc. stock trades during market volatilityQuarterly Profit Summary & Weekly Top Performers Watchlists - newser.com
Will Exelixis Inc. benefit from macro trends2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com
Exelixis Q2 2025 slides: cabozantinib franchise grows 19% YoY, NET launch gains traction By Investing.com - Investing.com South Africa
Earnings call transcript: Exelixis Q2 2025 sees solid revenue growth By Investing.com - Investing.com Philippines
Earnings call transcript: Exelixis Q2 2025 sees solid revenue growth - Investing.com
Key metrics from Exelixis Inc.’s quarterly data2025 Price Targets & AI Optimized Trading Strategy Guides - newser.com
How Exelixis Inc. (EX9) stock reacts to monetary easingWeekly Stock Report & AI Enhanced Trade Execution Alerts - newser.com
Why Exelixis Inc. is moving todayPortfolio Update Summary & AI Powered Trade Plan Recommendations - newser.com
Is Exelixis Inc. stock cheap at current valuation2025 Geopolitical Influence & Community Consensus Trade Signals - newser.com
What recovery options are there for Exelixis Inc.Quarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com
Exelixis Inc expected to post earnings of 61 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL) - The Globe and Mail
Exelixis Inc Stock Analysis and ForecastStock Market Trends & Small Investment Growth Plans - earlytimes.in
Exelixis' Q4 Loss Widens as Investors Await Key Trial Data - AOL.com
Using RSI to spot recovery in Exelixis Inc.Layoff News & Weekly Momentum Stock Picks - newser.com
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - GlobeNewswire Inc.
Best data tools to analyze Exelixis Inc. stock2025 Retail Activity & Real-Time Stock Entry Alerts - newser.com
How Exelixis Inc. (EX9) stock reacts to new regulationsMarket Risk Analysis & High Accuracy Swing Entry Alerts - newser.com
How buyback programs support Exelixis Inc. (EX9) stockM&A Rumor & AI Driven Price Forecasts - newser.com
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):